AveXis doses first patient in Phase I SMA trial

AveXis Inc. (NASDAQ:AVXS) detailed plans to expand its clinical development program for spinal muscular atrophy gene therapy candidate AVXS-101 via four additional clinical trials.

The company confirmed it has dosed the first patient in the U.S. Phase I STRONG study of intrathecal AVXS-101 to treat SMA type 2 in two age groups: less than

Read the full 537 word article

User Sign In